Loading organizations...
Based in Copenhagen, Denmark, Breye Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapies for the treatment of severe retinal vascular diseases. The enterprise specifically targets conditions such as diabetic retinopathy and age-related macular degeneration to provide more effective, non-invasive alternatives to standard intraocular injections. Operating without current revenue generation, the venture-backed biotech firm emerged from stealth mode in November 2022 after successfully closing a €4 million seed financing round. This initial capital injection was co-led by major institutional investors Novo Holdings and Sound Bioventures, who partnered with Independent Chairman Jim Millen to advance the clinical pipeline. Following initial preclinical proof-of-concept results, the organization is currently progressing its lead therapeutic asset toward an upcoming phase 1b clinical trial. Breye Therapeutics was officially founded in 2022 by chief executive officer Ulrik Mouritzen.
Breye Therapeutics has raised $4.1M across 1 funding round.
Breye Therapeutics has raised $4.1M in total across 1 funding round.
Breye Therapeutics has raised $4.1M in total across 1 funding round.
Breye Therapeutics's investors include Jørgen Søberg Petersen, Johan Kördel, BioInnovation Institute, Vaekstfonden.
Breye Therapeutics has raised $4.1M across 1 funding round. Most recently, it raised $4.1M Seed in November 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 11, 2022 | $4.1M Seed | Jørgen Søberg Petersen, Johan Kördel | BioInnovation Institute, Vaekstfonden |
